PDS Biotechnology Corporation (PDSB) reported a net loss of $9.8 million, or $0.18 per basic and diluted share, for the second quarter ended June 30, 2026. The company reported cash and cash equivalents of $5.6 million at quarter-end.
The clinical-stage biotechnology company said it is prioritizing development of PDS0301, its tumor-targeted IL-12 immunocytokine, and will cease further internal investment in PDS0101, including discontinuing the VERSATILE-003 Phase 3 trial.
- Research and development expense was $3.3 million, compared with $4.2 million a year earlier.
- General and administrative expense was $3.2 million, compared with $3.4 million a year earlier.
- Total operating expenses were $6.5 million, down from $7.6 million in the prior-year quarter.
- Net interest expense was $3.3 million, compared with $1.8 million in the prior-year quarter.
- The company said it intends to pursue strategic partnerships or other externally funded opportunities for continued development of PDS0101.
$PDSB Hedge Fund Activity
We have seen 19 institutional investors add shares of $PDSB stock to their portfolio, and 21 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 2,660,901 shares (-93.9%) from their portfolio in Q1 2026, for an estimated $1,609,845
- FOCUS PARTNERS WEALTH added 642,177 shares (+inf%) to their portfolio in Q2 2026, for an estimated $565,822
- MILITIA CAPITAL MANAGEMENT LLC added 331,800 shares (+inf%) to their portfolio in Q2 2026, for an estimated $292,348
- UBS GROUP AG removed 195,701 shares (-77.8%) from their portfolio in Q1 2026, for an estimated $118,399
- SQUAREPOINT OPS LLC removed 192,556 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $116,496
- GEODE CAPITAL MANAGEMENT, LLC removed 73,089 shares (-11.1%) from their portfolio in Q2 2026, for an estimated $64,398
- NINE MASTS CAPITAL LTD removed 67,507 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $59,480
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
